Ir para o conteúdo principal

Moderna (NASDAQ: MRNA) — Perfil da empresa, notícias e dados financeiros

Logo de Moderna
MRNA Moderna
Moderna primary media
Perfil da empresa

Moderna

Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA medicines and vaccines. The company utilizes proprietary messenger RNA technology platforms to design therapeutics and preventive vaccines targeting infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular ailments. Its commercial portfolio includes preventive vaccines for viral respiratory pathogens alongside a pipeline of clinical candidates across multiple therapeutic areas. The company maintains biomanufacturing, research, and commercial operations internationally.

Resumo

Public USParticipação acionária
2010Ano de fundação
1,001–5,000Funcionários
Cambridge, United StatesSede
Carregando mapa...
Presença global

Operações

Produtos e/ou serviços de Moderna

  • Respiratory Vaccines: Commercial production and global supply of messenger RNA vaccines protecting against respiratory viral infections, including formulations for COVID-19 and respiratory syncytial virus administered across international healthcare markets.
  • Infectious Disease Pipeline: Clinical development of investigational mRNA vaccines targeting latent and emerging pathogens, including cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and seasonal influenza strains.
  • Immuno-Oncology Therapeutics: Advancement of individualized neoantigen therapies and off-the-shelf mRNA cancer vaccines designed to stimulate targeted T-cell immune responses against specific tumor antigens in combination with checkpoint inhibitors.
  • Rare Disease Therapies: Development of systemic messenger RNA therapeutics designed to instruct human cells to produce functional intracellular or secreted proteins, addressing metabolic deficiencies such as propionic acidemia and methylmalonic acidemia.
  • Autoimmune and Cardiovascular Therapeutics: Clinical research into localized and systemic mRNA formulations designed to express therapeutic proteins, promote angiogenesis, or modulate immune pathways in heart failure, ischemic heart disease, and autoimmune conditions.
  • Manufacturing Facilities: Operation of specialized biomanufacturing plants and technological hubs, including facilities in Norwood, Massachusetts, dedicated to clinical supply production, lipid nanoparticle formulation, and large-scale commercial drug substance manufacturing.

equipe executiva do Moderna

  • Stéphane BancelCEO & Director
  • Stephen HogePresident
  • James M. MockChief Financial Officer
  • Shannon Thyme KlingerChief Legal Officer & Corporate Secretary
  • Juan AndresChief Operating Officer
  • Lavina TalukdarSenior VP & Head of Investor Relations
  • Chris RidleyVP & Global Head of Communications
  • Tracey FranklinChief People & Digital Technology Officer
  • Charbel HaberSenior VP & Head of Global Regulatory Science
  • Patrick Norman BergstedtSenior Vice President of Commercial Vaccines

Comunicados recentes

O que a Moderna (MRNA) comunicou ao mercado, do mais recente para o mais antigo.

  1. 8-K | Moderna, Inc.

Principais indicadores financeiros

Resultados divulgados pela Moderna, em USD.

Cap. de mercado
93,6 bi
Receita (TTM)
2,5 bi
P/L
—
LPA (diluído, TTM)
-6.5
Dividend yield
—
Margem de lucro
-110.5%
Receita e lucro anuais da Moderna
Fim do ano fiscalReceitaResultado operacionalLucro líquido
1,9 bi-3,1 bi-2,8 bi
3,2 bi-3,9 bi-3,6 bi
6,8 bi-4,2 bi-4,7 bi
18,9 bi9,4 bi8,4 bi